Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 667-685 doi:10.1007/s11684-022-0960-z

Abstract 71 PDF 22

Recent advances in systemic lupus erythematosus and microbiota: from bench to bedside

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 686-700 doi:10.1007/s11684-022-0957-7

Abstract 41 PDF 4

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 701-713 doi:10.1007/s11684-022-0951-0

Abstract 35 PDF 28

New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 714-722 doi:10.1007/s11684-021-0888-8

Abstract 60 PDF 2

Increased expression of coronin-1a in amyotrophic lateral sclerosis: a potential diagnostic biomarker and therapeutic target

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 723-735 doi:10.1007/s11684-021-0905-y

Abstract 73 PDF 5

Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients with pneumoconiosis: a pilot double-blind, randomized, and placebo-controlled study

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 736-744 doi:10.1007/s11684-021-0870-5

Abstract 68 PDF 3

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 745-759 doi:10.1007/s11684-021-0880-3

Abstract 59 PDF 7

Outcomes of patients awaiting lung transplantation after the implementation of donation after brain death at a single Chinese center

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 760-765 doi:10.1007/s11684-021-0899-5

Abstract 124 PDF 5

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi:10.1007/s11684-021-0916-8

Abstract 34 PDF 8

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 773-783 doi:10.1007/s11684-021-0902-1

Abstract 123 PDF 11

Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 784-798 doi:10.1007/s11684-021-0911-0

Abstract 69 PDF 19

Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 799-807 doi:10.1007/s11684-021-0849-2

Abstract 44 PDF 2

Novel variants in LAMA3 and COL7A1 and recurrent variant in KRT5 underlying epidermolysis bullosa in five Chinese families

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 808-814 doi:10.1007/s11684-021-0878-x

Abstract 89 PDF 1

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi:10.1007/s11684-021-0891-0

Abstract 75 PDF 31